NO20090818L - Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav - Google Patents

Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav

Info

Publication number
NO20090818L
NO20090818L NO20090818A NO20090818A NO20090818L NO 20090818 L NO20090818 L NO 20090818L NO 20090818 A NO20090818 A NO 20090818A NO 20090818 A NO20090818 A NO 20090818A NO 20090818 L NO20090818 L NO 20090818L
Authority
NO
Norway
Prior art keywords
methods
herv
immune response
polypeptide compositions
endogenous retrovirus
Prior art date
Application number
NO20090818A
Other languages
English (en)
Norwegian (no)
Inventor
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Jack Lenz
Frederick M Hecht
Original Assignee
Seth Rakoff-Nahoum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seth Rakoff-Nahoum filed Critical Seth Rakoff-Nahoum
Publication of NO20090818L publication Critical patent/NO20090818L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20090818A 2006-07-21 2009-02-20 Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav NO20090818L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
PCT/US2007/016403 WO2008011120A2 (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20090818L true NO20090818L (no) 2009-04-17

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090818A NO20090818L (no) 2006-07-21 2009-02-20 Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav

Country Status (15)

Country Link
US (2) US20080171061A1 (https=)
EP (1) EP2046380A4 (https=)
JP (1) JP2009544614A (https=)
KR (1) KR20090060410A (https=)
CN (1) CN101557823A (https=)
AU (1) AU2007275693A1 (https=)
BR (1) BRPI0714714A2 (https=)
CA (1) CA2658393A1 (https=)
IL (1) IL196516A0 (https=)
MX (1) MX2009000659A (https=)
NO (1) NO20090818L (https=)
RU (1) RU2009106089A (https=)
SG (1) SG173997A1 (https=)
WO (1) WO2008011120A2 (https=)
ZA (1) ZA200900379B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
US8323659B2 (en) * 2008-09-18 2012-12-04 Keio University Method for diagnosing and/or treating tumor
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102593047B1 (ko) 2012-01-26 2023-10-24 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11779603B2 (en) 2016-06-30 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HERV-E reactive T cell receptors and methods of use
CA3033262A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
CN110121336A (zh) 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
CA3058807A1 (en) * 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
DK3676285T3 (da) 2017-09-01 2026-01-19 Inprother Aps Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020049169A1 (en) * 2018-09-06 2020-03-12 Centre Léon-Bérard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2024108001A2 (en) * 2022-11-16 2024-05-23 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
US20260035415A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20030162263A1 (en) * 2001-09-06 2003-08-28 Marc Dupuis Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
US20070037147A1 (en) * 2001-12-07 2007-02-15 Pablo Garcia Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
US20130323279A1 (en) 2013-12-05
ZA200900379B (en) 2010-08-25
EP2046380A2 (en) 2009-04-15
WO2008011120A2 (en) 2008-01-24
RU2009106089A (ru) 2010-08-27
US20080171061A1 (en) 2008-07-17
JP2009544614A (ja) 2009-12-17
BRPI0714714A2 (pt) 2013-04-09
SG173997A1 (en) 2011-09-29
AU2007275693A1 (en) 2008-01-24
CN101557823A (zh) 2009-10-14
WO2008011120A3 (en) 2008-11-06
CA2658393A1 (en) 2008-01-24
EP2046380A4 (en) 2013-05-01
IL196516A0 (en) 2011-08-01
MX2009000659A (es) 2009-06-08
KR20090060410A (ko) 2009-06-12

Similar Documents

Publication Publication Date Title
NO20090818L (no) Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav
MX2010003110A (es) Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
MX2024005677A (es) Receptores de celulas t que reconocen p53 mutado.
WO2021198706A3 (en) Coronavirus vaccines
JP2019146574A5 (https=)
EP4424710A3 (en) Nyeso tcr
RU2016146198A (ru) Терапевтические dll4-связывающие белки
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
BRPI0512286B8 (pt) proteínas quiméricas inibidoras da angiogênese e o uso
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
NZ576467A (en) Smoothened polypeptides and methods of use
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
RU2012157303A (ru) Адаптированная рекомбиназа для рекомбинации асимметричных участков-мишеней во множестве штаммов ретровирусов
HUE042053T2 (hu) Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
EA202092589A2 (ru) Cxcr2-связывающие полипептиды
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
NO20063026L (no) Antistoffer
DE502005006284D1 (de) Keratin-bindende polypeptide
EA201591213A1 (ru) Вакцины против вируса гепатита b
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
NO20063556L (no) HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
WO2008113970A3 (en) Peptides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application